Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, ...

Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

Learn how Mounjaro (tirzepatide) may reverse pre-diabetes in young adults in India, its benefits, and why early action is key.

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

The Mounjaro buzz is now distinctly reaching Indian A-listers and wellness-conscious urban adults, sparking conversations about its potential ...

India's weight-loss game is getting serious! The country's anti-obesity market is now worth ₹628 crore, and it's climbing ...

The trial enrolled more than 13,000 participants across 30 countries and lasted more than four and a half years. It was also the largest and longest study of tirzepatide --- the active ingredient in ...

Weight loss injectables such as Ozempic and Mounjaro are gaining popularity in India But are they a sustainable solution or a ...

Miracle’ drugs used for weight-loss like Semaglutide and Tirzepatide—better known by their brand names Ozempic and ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Indian pharmaceutical firms are gearing up to capitalize on the growing demand for weight-loss drugs, with the market potentially reaching $1bn.